Hsbc Holdings PLC Grows Stock Holdings in LivaNova PLC $LIVN

Hsbc Holdings PLC lifted its holdings in LivaNova PLC (NASDAQ:LIVN) by 260.6% during the fourth quarter, Holdings Channel reports. The fund owned 20,301 shares of the company’s stock after buying an additional 14,671 shares during the quarter. Hsbc Holdings PLC’s holdings in LivaNova were worth $1,255,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the business. Hantz Financial Services Inc. lifted its position in LivaNova by 159.9% during the fourth quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock valued at $27,000 after purchasing an additional 267 shares during the period. State of Wyoming acquired a new stake in LivaNova during the 2nd quarter worth about $31,000. EverSource Wealth Advisors LLC raised its stake in shares of LivaNova by 998.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after buying an additional 639 shares during the last quarter. Quarry LP purchased a new position in shares of LivaNova during the 3rd quarter valued at about $36,000. Finally, Covestor Ltd raised its stake in shares of LivaNova by 108.6% during the 4th quarter. Covestor Ltd now owns 753 shares of the company’s stock valued at $46,000 after buying an additional 392 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Insider Transactions at LivaNova

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total value of $136,350.00. Following the sale, the director directly owned 7,228 shares of the company’s stock, valued at approximately $547,521. This trade represents a 19.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.35% of the company’s stock.

Analysts Set New Price Targets

LIVN has been the topic of a number of recent research reports. Freedom Capital upgraded LivaNova to a “hold” rating in a research note on Tuesday, June 30th. Mizuho lifted their price target on LivaNova from $85.00 to $90.00 and gave the company an “outperform” rating in a research report on Thursday, May 7th. Robert W. Baird decreased their price target on LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Weiss Ratings upgraded LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research report on Thursday, May 7th. Finally, Barclays raised their price objective on shares of LivaNova from $73.00 to $76.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 7th. Six research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $80.75.

LivaNova Stock Performance

LIVN stock opened at $82.56 on Monday. The company’s 50-day simple moving average is $76.00 and its 200-day simple moving average is $68.36. The company has a quick ratio of 1.11, a current ratio of 1.33 and a debt-to-equity ratio of 0.24. LivaNova PLC has a 52-week low of $41.01 and a 52-week high of $85.27. The firm has a market cap of $4.54 billion, a P/E ratio of 42.34 and a beta of 0.86.

LivaNova (NASDAQ:LIVN) last posted its earnings results on Wednesday, May 6th. The company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.13. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The firm had revenue of $362.26 million for the quarter, compared to analysts’ expectations of $346.05 million. During the same period last year, the firm earned $0.88 EPS. The company’s quarterly revenue was up 14.3% on a year-over-year basis. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. As a group, equities analysts forecast that LivaNova PLC will post 3.73 EPS for the current fiscal year.

LivaNova Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.